8-K: Flora Growth Corp. Completes First Closing of TruHC Pharma Acquisition

Flora Growth Corp. finalized the first stage of its acquisition of TruHC Pharma, issuing 2,770,562 common shares valued at $6.4 million.

Summary

• Flora Growth Corp. completed the first closing of its acquisition of TruHC Pharma GmbH on April 22, 2024.
• The company issued 2,770,562 common shares in exchange for TruHC Pharma, valued at $6.4 million based on a share price of $2.31 on March 28, 2024.
• 2,135,199 shares were distributed to Ronald D. Schmeichel, James G. Eaton, and Donald Schmeichel as directed by the seller.
• The shares issued in the first closing represent 19.99% of Flora Growth's outstanding shares before the agreement.
• A second closing will occur after shareholder approval at the next special or annual general meeting, where an additional 635,363 shares will be issued.

Sentiment

Score: 7

Explanation: The document indicates a positive step for the company with the completion of the first closing of the acquisition, but there is still some uncertainty regarding the second closing and shareholder approval.

Positives

• The acquisition of TruHC Pharma marks a significant step in Flora Growth's expansion strategy.
• The first closing was completed successfully, indicating progress in the acquisition process.
• The issuance of shares for the acquisition aligns with the terms of the purchase agreement.

Risks

• The second closing is contingent on shareholder approval, which introduces uncertainty.
• The company is required to convene a shareholder meeting to approve the second closing, which may take time and resources.

Future Outlook

The company will need to convene a shareholder meeting to approve the second closing of the acquisition, which will involve the issuance of an additional 635,363 shares.

Management Comments

• The company is required to take all necessary steps and make commercial best efforts to convene a shareholder meeting as soon as reasonably practicable to approve the Second Closing.

Industry Context

This acquisition reflects a trend of consolidation within the cannabis and pharmaceutical sectors, where companies are expanding their reach through strategic acquisitions.

Comparison to Industry Standards

• The acquisition of TruHC Pharma is similar to other strategic acquisitions in the pharmaceutical and cannabis industries, where companies seek to expand their product portfolios and market reach.
• The use of stock as consideration is a common practice in acquisitions, especially for companies looking to preserve cash.
• The requirement for shareholder approval for the second closing is standard practice for transactions that involve a significant issuance of shares.

Stakeholder Impact

• Shareholders will be impacted by the dilution of shares due to the issuance of new shares for the acquisition.
• The acquisition could potentially lead to increased revenue and growth for the company, benefiting shareholders in the long term.

Next Steps

• The company will convene a shareholder meeting to approve the second closing of the acquisition.
• The company will issue an additional 635,363 shares upon shareholder approval.

Key Dates

Keywords

acquisition, TruHC Pharma, share issuance, common shares, closing, shareholder approval, Flora Growth Corp